6-甲基-1,3-苯并二氧戊环-5-醇 | 7622-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 6-甲基-1,3-苯并二氧戊环-5-醇
• 英文名称: 6-methylbenzo[d][1,3]dioxol-5-ol
• 英文别名: 2-Methyl-4,5-methylendioxy-phenol；6-Methyl-1,3-benzodioxol-5-ol
• CAS: 7622-31-3
• 化学式: C₈H₈O₃
• mdl: MFCD18805456
• 分子量: 152.15
• InChiKey: JRFWKGNYNPPPLF-UHFFFAOYSA-N

物化性质

• 沸点：
  282.9±39.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  2-氨基-N-(2-氯-6-甲基苯基)-5-噻唑酰胺	4,5-methylenedioxy-2-hydroxybenzaldehyde	4720-68-7	C8H6O4	166.133

反应信息

• 作为反应物：
  描述：

  6-甲基-1,3-苯并二氧戊环-5-醇 、 2-氯-4-硝基苯甲酰氯 以 二氯甲烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel 7H-benzo [c] [1, 3] dioxolo [4, 5-f] chromen-7-one derivatives with potential anti-tumor activity

  摘要：

  In this study, a series of novel 7H-benzo [c] [1,3] dioxolo [4, 5-f] chromen-7-one derivatives were obtained by structural modification of the lead compounds with Fissitungfine B. A total 15 compounds were designed, synthesized and evaluated as inhibitors of tumor. These target compounds have the novel chemical structures that named three six-membered rings including one lactone six-membered ring. In vitro assay, the results showed that the target compounds have a broad spectrum and strong of anti-tumor activity. Such as the target compound 4n to MCF-7 was IC₅₀ = 0.35 ± 0.01 μM, to A-549 was IC₅₀ = 0.37 ± 0.01 μM, to Hela was IC₅₀ = 0.56 ± 0.02 μM, to MDC-803 was IC₅₀ = 0.53 ± 0.02 μM and COLO-205 was IC₅₀ = 0.50 ± 0.02 μM in vitro. At the same time, in vivo anti-tumor activity assay results showed that the target compounds had a good inhibitory effect on tumor growth. Among them, the target compound 4n had the best anti-tumor activity, it could inhibit tumor growth well at a low dose. The target compound 4n could be used as a candidate drug for further research and development, in order to be used as early as application in the clinical treatment of tumors.

  DOI：

  10.1016/j.bioorg.2020.104381
• 作为产物：
  描述：

  2-氨基-N-(2-氯-6-甲基苯基)-5-噻唑酰胺 在 溶剂黄146 、 锌 作用下， 以 水 为溶剂， 反应 2.0h， 以73%的产率得到6-甲基-1,3-苯并二氧戊环-5-醇
  参考文献：
  名称：

  芝麻酚C-6位部分衍生物的合成及抗氧化能力

  摘要：

  几种合成方法（氨基甲基化、烷基化、缩合等）已被用于合成基于芝麻酚( 1 )、天然苯酚的衍生物。一套方法，包括通过抑制动物脂质起始氧化的能力、自由基清除活性、Fe 2+ -螯合能力以及膜保护活性的比较评估来研究抗氧化活性 (AOA) H 2 O 2 的条件诱导小鼠红细胞（RBC）溶血，用于分析合成化合物的抗氧化潜力。合成的衍生物在列出的测试系统中表现出不同的活性，我们已经确定了最有希望对其药理特性进行详细研究的化合物。

  DOI：

  10.1002/cbdv.202100221

文献信息

• SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF
  申请人：Shi Xiulan

  公开号：US20120142921A1

  公开（公告）日：2012-06-07

  The invention relates to substituted hydrazide compounds as shown by general formula I, including geometrical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and use of the same, wherein the substitutents Ar and R have the same meanings as given in the Description. The invention further relates to the use of compounds of general formula I in the preparation of medicament for the treatment and/or prevention of cancer and other proliferative diseases.

  本发明涉及通式I所示的取代肼化合物，包括几何异构体、药学上可接受的盐、水合物、溶剂合物或前药，以及其使用，其中取代基Ar和R的含义与说明中给出的相同。本发明还涉及通式I化合物在制备用于治疗和/或预防癌症和其他增殖性疾病的药物中的使用。
• Isoxazole Compounds As Inhibitors Of Heat Shock Proteins
  申请人：Vernalis (R&D) Limited

  公开号：US20130289026A1

  公开（公告）日：2013-10-31

  Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R 1 , is a group of formula (IA): —Ar 1 -(Alk 1 ) p -(Z) r -(Alk 2 ) s -Q, wherein in any compatible combination Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 6 alkylene or C 2 -C 6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO.sub.2-, —C(═O)O—, —C(═O)NR A —, —C(═S)NR A —, —SO 2 NR A —, —NR A C(═O)—, —NR A SO 2 — or —NR A — wherein R A is hydrogen or C 1 -C 6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk 1 )p-(Z) r -(Alk 2 ) s -Q wherein Q, Alk 1 , Alk 2 , Z, p, r and s are as defined above in relation to group (IA); and R 3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, or C 1 -C 6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

  式（A）或（B）的异噁唑类化合物是HSP90活性抑制剂，可用于治疗癌症等疾病，其中R1是以下式子的基团（IA）：—Ar1-（Alk1）p-（Z）r-（Alk2）s-Q，其中在任何兼容的组合中，Ar1是可选取代的芳基或杂环芳基基团，Alk1和Alk2是可选取代的二价C1-C6烷基或C2-C6烯基基团，p、r和s独立地为0或1，Z是-0-、—S—、—（C═O）—、—（C═S）—、—SO.sub.2-、—C（═O）O—、—C（═O）NRA—、—C（═S）NRA—、—SO2NRA—、—NRAC（═O）—、—NRASO2—或—NRA—，其中RA为氢或C1-C6烷基，Q为氢或可选取代的碳环或杂环基团；R2为（i）上述式（IA）的基团或（ii）一个羧酰胺基团；或（iii）非芳香碳环或杂环环，其中一个环碳原子是可选取代的，和/或一个环氮原子是可选取代的，由式-(Alk1)p-(Z)r-(Alk2)s-Q的基团定义，其中Q、Alk1、Alk2、Z、p、r和s如上所述与基团（IA）相关；R3为氢、可选取代的环烷基、环烯基、C1-C6烷基、C1-C6烯基或C1-C6炔基；或羧基、羧酰胺基或羧酸酯基团。
• Anionic dyes and hair dye compositions containing them
  申请人：DyStar Textilfarben GmbH & Co. Deutschland KG

  公开号：EP2108406A1

  公开（公告）日：2009-10-14

  The present invention refers to dyestuffs of the formula (I) and its tautomeric forms, wherein D is a group of the formula D1, D2, D3, D4 or D5 wherein T, X, Y, Z, A1 to A4, G, R1, R5, R7 to R11, m, n, o, p, q, r, s and t are defined as given in claim 1, a process for their manufacture and hair dye compositions containing them.

  本发明涉及式 (I) 的染料 及其同分异构体，其中 D 是式 D1、D2、D3、D4 或 D5 的基团 其中 T、X、Y、Z、A1 至 A4、G、R1、R5、R7 至 R11、m、n、o、p、q、r、s 和 t 的定义如权利要求 1 所述，它们的制造工艺和含有它们的染发组合物。
• SUBSTITUTED HYDRAZIDE COMPOUNDS AND APPLICATION THEREOF
  申请人：Shenyang J & Health Pharmaceutical Co., Ltd.

  公开号：EP2468730A1

  公开（公告）日：2012-06-27

  The invention relates to substituted hydrazide compounds as shown by general formula I, including geometrical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and use of the same, wherein the substitutents Ar and R having the same meanings as given in the Description. T The invention further relates to the use of compounds of general formula I in the preparation of medicament for the treatment and/or prevention of cancer and other proliferative diseases.

  本发明涉及通式I所示的取代酰肼化合物，包括几何异构体，其药学上可接受的盐、水合物、溶液或原药，以及其用途，其中取代基Ar和R的含义与说明书中给出的相同。T 本发明进一步涉及通式 I 化合物在制备治疗和/或预防癌症和其它增殖性疾病的药物中的用途。
• US3962415A
  申请人：——

  公开号：US3962415A

  公开（公告）日：1976-06-08